Livforsakringsbolaget Skandia Omsesidigt Buys 200 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Livforsakringsbolaget Skandia Omsesidigt grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 281.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 271 shares of the medical research company’s stock after acquiring an additional 200 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Bio-Rad Laboratories were worth $91,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. UMB Bank n.a. boosted its position in shares of Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Fulton Bank N.A. bought a new stake in shares of Bio-Rad Laboratories during the 3rd quarter valued at about $224,000. RK Asset Management LLC bought a new stake in shares of Bio-Rad Laboratories during the 3rd quarter valued at about $5,198,000. GAMMA Investing LLC boosted its position in shares of Bio-Rad Laboratories by 66.7% during the 3rd quarter. GAMMA Investing LLC now owns 535 shares of the medical research company’s stock valued at $179,000 after acquiring an additional 214 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its position in shares of Bio-Rad Laboratories by 20.6% during the 3rd quarter. Handelsbanken Fonder AB now owns 5,272 shares of the medical research company’s stock valued at $1,764,000 after acquiring an additional 900 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Shares of NYSE BIO opened at $342.16 on Wednesday. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The stock’s 50-day moving average is $329.41 and its 200 day moving average is $306.82. The stock has a market cap of $9.76 billion, a price-to-earnings ratio of -33.03 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a 1-year low of $261.59 and a 1-year high of $364.24.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, August 1st. The medical research company reported $3.11 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.99. The business had revenue of $638.50 million for the quarter, compared to analysts’ expectations of $645.79 million. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The business’s quarterly revenue was down 6.3% on a year-over-year basis. During the same period in the previous year, the firm earned $3.00 EPS. On average, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 17.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BIO. Citigroup upgraded Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and lifted their price target for the company from $350.00 to $400.00 in a research report on Tuesday, October 1st. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Royal Bank of Canada reissued an “outperform” rating and set a $401.00 price objective on shares of Bio-Rad Laboratories in a report on Friday, August 16th. Finally, Wells Fargo & Company began coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective on the stock. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Bio-Rad Laboratories has an average rating of “Moderate Buy” and a consensus target price of $368.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.